Tesamorelin Reduces Visceral Adipose Tissue in Patients with HIV-Associated Lipodystrophy

This is FDA-approved medicine, not experimental research—and the data is remarkable. Tesamorelin targets visceral fat, the deep abdominal fat wrapped around your organs that's metabolically toxic. This isn't about aesthetics; visceral fat drives insulin resistance, cardiovascular disease, and metabolic syndrome. What makes this study powerful is that it shows growth hormone pathway modulation can selectively mobilize this fat without the muscle loss and metabolic damage that come with extreme caloric restriction. The trial used CT imaging—gold standard, no guessing—in HIV patients with severe metabolic dysfunction. If it works in that population, the implications for healthy aging and metabolic optimization are significant. This is guidance backed by human clinical evidence, not theory.

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that's FDA-approved specifically for reducing excess abdominal fat in HIV patients with lipodystrophy. This 2010 trial was part of the pivotal research that led to its approval. HIV lipodystrophy—characterized by abnormal fat accumulation, especially visceral fat—serves as an extreme model of the metabolic fat accumulation that occurs with aging and insulin resistance. The trial used gold-standard CT imaging to precisely measure visceral versus subcutaneous fat, providing objective data rather than relying on weight or waist measurements. Importantly, the visceral fat reduction persisted throughout the 6-month treatment period and was accompanied by improvements in metabolic markers, suggesting the changes were physiologically meaningful, not just cosmetic.

Effects of tesamorelin on body composition in HIV-infected patients with excess abdominal fat: a randomized placebo-controlled trial